A Case Report of Capecitabine-Associated Bowel Inflammation With a Novel Mutation of the DPYD Gene

Abstract

Capecitabine is a fluoropyrimidine used in chemotherapeutic regiments in patients with colorectal cancer. Diarrhea and hand-foot syndrome are common adverse effects of capecitabine treatment in patients with colorectal cancer,1,2 whereas steatohepatitis is rather uncommon. In this case report, we present the case of a patient with colon cancer receiving adjuvant capecitabine treatment and suffering from severe therapy-refractory diarrhea, hand-foot syndrome, and steatosis hepatis caused by a novel mutation of the DPYD gene and a swelling of the bowel, which presented as an unusually early relapse tumor.